The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,069,261 in first-year total cost, median $443,654.
Most frequent study sections
- Cancer Immunopathology and Immunotherapy Study Section[CII]2
- Special Emphasis Panel[ZRG1 OTC-M (08)]2
- Special Emphasis Panel[ZRG1 OBT-K (02)]1
Most frequent institutions
- CINCINNATI CHILDRENS HOSP MED CTR1
- DUKE UNIVERSITY1
- SLOAN-KETTERING INST CAN RESEARCH1
- UNIVERSITY OF CALIFORNIA, SAN DIEGO1
- UNIVERSITY OF UTAH1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Targeting replication stress signaling to overcome immune evasion in small cell lung cancer1R01CA258784-01 | SEN, TRIPARNA | SLOAN-KETTERING INST CAN RESEARCH, NY | $513,261 | ZRG1 |
| 2020 | Reprogramming the Tumor Microenvironment in Ovarian Cancer1R01CA254342-01 | SCHLAEPFER, DAVID D | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $443,654 | ZRG1 |
| 2020 | Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy1R37CA249085-01 | HANKS, BRENT ALLEN | DUKE UNIVERSITY, NC | $317,373 | ZRG1 |
| 2019 | The role of transcription elongation defects in immunotherapy resistance in cancers1R01CA234038-01A1 | GUO, FUKUNZHENG, YI | CINCINNATI CHILDRENS HOSP MED CTR, OH | $446,129 | CII |
| 2018 | Role of RON kinase in anti-tumor immune responses1R01CA223245-01A1 | WELM, ALANA L | UNIVERSITY OF UTAH, UT | $348,844 | CII |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.